Precigen (PGEN) Hisse Fiyat
Precigen Fiyat
Precigen, son 14 yılda gelirini yıllık %1,4 artırarak 9,68 M USD seviyesine taşıdı. Precigen için net marj, %-2.588,2 ile birkaç yıl önceki %-646,0 seviyesine göre geriledi. Precigen için 12 aylık konsensüs fiyat hedefi 18,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %192,9 üzerinde bir seviyeye denk geliyor. 10 analistten 8 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Precigen hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Precigen iş modeli ve hisse analizi
Precigen hakkında sık sorulan sorular
Precigen Inc is a biotechnology company focused on utilizing its proprietary synthetic biology technology to develop innovative solutions to global challenges. The business model of Precigen revolves around leveraging its expertise in gene and cell therapy, as well as its advanced bioinformatics capabilities, to address critical needs in healthcare, agriculture, and environmental conservation. With a strong emphasis on precision medicine, the company aims to develop personalized therapies and genetic engineering solutions. Precigen Inc collaborates with various partners to accelerate the development and commercialization of its products and services, aiming to make a positive impact on society through cutting-edge biotechnology advancements.
Precigen Inc is primarily active in the biotechnology industry. As a leading biotech company, Precigen focuses on developing advanced gene and cell therapies, genetic medicines, and agricultural biotechnology solutions. The company harnesses the power of innovative gene editing platforms to address significant unmet needs in healthcare and food production sectors. Precigen Inc leverages its cutting-edge technologies and extensive expertise to create transformative solutions for various genetic disorders, chronic diseases, and sustainable agriculture practices. With its commitment to innovation and scientific progress, Precigen Inc continues to play a vital role in shaping the biotechnology landscape.
The main competitors of Precigen Inc in the market include companies like Intrexon Corporation, Editas Medicine, CRISPR Therapeutics, and Sangamo Therapeutics.
Precigen Inc, formerly known as Intrexon Corporation, is a biotechnology company based in Germantown, Maryland. Established in 1998, Precigen focuses on applying synthetic biology to solve complex problems across various industries. The company is driven by a mission to create biologically-based solutions to improve the quality of life and promote sustainability. Precigen has expertise in the development and commercialization of advanced gene and cellular therapies, as well as agricultural biotech solutions. With its innovative approach and cutting-edge technologies, Precigen has established itself as a leader in the field of synthetic biology, continuously striving to push boundaries and make a positive impact on the world.
Precigen Inc, formerly known as Intrexon Corporation, has achieved several noteworthy milestones throughout its history. The company, a leader in synthetic biology, has successfully developed and commercialized various advanced technologies and solutions. Precigen Inc has made significant breakthroughs in the areas of gene and cell therapy, as well as synthetic gene technologies. These accomplishments include the successful clinical trials of their CAR-T therapy candidates, the development of their UltraVector® platform, and the creation of novel genetically modified organisms. Precigen Inc's continuous dedication to innovation and cutting-edge science has positioned them as one of the prominent players in the field.
Precigen Inc is primarily present in the United States and has its headquarters in Germantown, Maryland.
Precigen Inc represents a strong commitment to innovation, integrity, and social responsibility. As a leading biotechnology company, Precigen pioneers advancements in the field of genetic research. With a dedicated focus on developing therapies and solutions for human health, they prioritize scientific excellence and cutting-edge technology. Led by a team of experts, Precigen emphasizes collaboration and strategic partnerships to achieve their mission of transforming lives through innovative healthcare solutions. Through their dedication to improving global health outcomes and their unwavering dedication to their core values, Precigen Inc stands as a trusted name in the biotech industry.
Analistler şu anda Precigen hissesi için ortalama 18,00 USD hedef fiyat belirliyor (medyan: 18,00 USD); bu, son fiyata göre +188,5 % anlamına gelir. Konsensüs 10 analist notuna dayanır.
10 analist şu anda Precigen hissesini değerlendiriyor: 8 al, 2 tut, 0 sat öneriyor. 2026 için analistler Precigen şirketinin 238,71 M USD gelir ve 0,19 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Precigen hissesi 5,49 EUR (6,14 USD) seviyesindedir.
Precigen hissesi (PGEN) 5 borsada işlem görür, bunlar arasında: NASDAQ (PGEN), SIX (Zürich) (I5X.SW), Frankfurt (I5X), München (I5X.MU), Düsseldorf (I5X.DU).
Precigen Inc, founded in 2000, is a biotechnology company headquartered in Germantown, Maryland. The company specializes in the development and application of gene editing technologies used in the therapy of severe diseases and genetic disorders. Precigen's business model is based on four main areas: therapeutic product development, agricultural biotechnology, industrial biotechnology, and research and development of genomic technology. Precigen develops therapeutics aimed at curing or alleviating serious diseases such as cancer and genetic disorders using its proprietary gene editing technology platforms like UltraPrecise, ActoBiotics, and X-Press. The company also works in agricultural biotechnology to develop innovative solutions for improving agricultural yields and promoting sustainable farming. In industrial biotechnology, Precigen leverages its expertise to contribute to the development of renewable energy and biofuels. The company explores and develops new technologies in genomics for diagnostic, therapeutic, and disease prevention purposes. Precigen emphasizes the ethical and social aspects of genetic research. Additionally, the company offers products and services based on its technology platforms, such as UltraVector, a proprietary vector design tool that supports DNA construction and gene editing processes. Precigen also holds a license for obtaining plasmid DNA, which helps reduce costs in the production of therapeutics or biotherapeutics. Overall, Precigen has developed a wide range of technologies and applications to assist customers in overcoming complex challenges in various fields, with a focus on gene editing technology and its applications in therapy, agriculture, industrial biotechnology, and genomic research.
beklenen'nin Precigen hasılatı 238,71 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Precigen karı 60,63 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Precigen'nin Fiyat/Kazanç (F/K) oranı şu anda 31,72'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Precigen hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Precigen'nin Fiyat/Satış (F/S) oranı şu anda 8,06'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Precigen hisse senedinin değerleme metriği olarak hizmet eder.
Precigen'nin Eulerpool Kalite Puanı 2/10'dur.
Precigen'nin ISIN'i US74017N1054'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Precigen'nin WKN'i A2PZG1'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Precigen'nin ticker'ı PGEN'dir. Ticker sembolü, Precigen hisseleri borsada işlem görmek için kullanılır.
Precigen Hissesi
Precigen Emsaller Grubu
Precigen Ticker
Precigen FIGI
Precigen'nin tüm temel göstergeleri ve derinlemesine analizi
Precigen hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Precigen şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: